Bone morphogenetic protein-2 (BMP-2), a transforming growth factor-β superfamily member cytokine, plays a key role both in vascular development and in pathophysiological processes. However, the effects and mechanisms of angiotensin II (Ang II) on BMP-2 expression remain unknown in human umbilical vein endothelial cells (HUVECs). Here we show that Ang II treatment significantly increased BMP-2 expression, associated with NF-κB activation, which was suppressed by treatment with pyrrolidine dithiocarbamate (PDTC) or irbesartan. Furthermore, the increased levels of MDA (malondialdehyde) in conditioned media and the decrease in activities of total superoxide dismutases (SOD) caused by Ang II were reversed by irbesartan or PDTC treatment. Our findings indicate that Ang II-induced BMP-2 expression might contribute to NF-κB activation. BMP-2 expression induced by Ang II might involve excessive oxidative stress.
Introduction
Vascular calcification is highly correlated with atherosclerosis and is a significant predictor of cardiovascular morbidity and mortality. 1, 2 Bone morphogenetic protein-2 (BMP-2), a transforming growth factor-β superfamily member cytokine, plays an important role both in vascular development and in pathophysiological processes. 3 Many studies have confirmed that BMP-2 is a strong basic causative factor in vascular calcification. BMP-2 induction in the vasculature may be related to oxidative stress, inflammation, hyperglycemia and hyperlipidemia. [4] [5] [6] [7] Angiotensin II (Ang II) plays a key role in the regulation of the vascular inflammatory response by activating the recruitment of inflammatory cells to injured arteries and is also capable of promoting inflammation indirectly through the stimulation of several transcription factors. 8, 9 For example, nuclear factor-κB is regulated by Ang II, which plays an important role in the control of numerous genes, including cytokines, chemokines, adhesion molecules, and angiotensinogen. 10 However, the effects and mechanisms of Ang II on BMP-2 expression remain unknown in human umbilical vein endothelial cells (HUVECs). The aim of our study is to investigate the effects of Ang II on BMP-2 expression. We also used pyrrolidine dithiocarbamate (PDTC), an agent that inhibits activation of nuclear factor-κB, to examine the relationship between BMP-2 expression and NF-κB activation in this study.
Inhibition of the renin-angiotensin-aldosterone system has induced beneficial effects on endothelial function in animals and humans. Ang II receptor blockers (ARB) have been found to reduce the coronary atherosclerotic plaque burden in animal models, 11, 12 so we investigated some potentially protective effects of irbesartan on Ang II-induced BMP-2 expression.
Materials and methods

Culture and treatment of HUVECs
HUVECs were cultured in Medium 200 containing low serum growth supplement (LSGS; Cascade Biologics). The experiments were performed using HUVECs after five to seven passages. The cultured cells were incubated for 4 hours with the following groups: control group (treated with media alone); PDTC group (treated with 15 μmol/l PDTC alone); irbesartan group (treated with 10 μmol/l irbesartan alone); Ang II group (treated with Ang II 1.0 μmol/l); Ang II + PDTC group (treated with Ang II 1.0 μmol/l + PDTC 15 μmol/l); Ang II + irbesartan group (treated with Ang II 1.0 μmol/l + irbesartan 10 μmol/l).
BMP-2 mRNA expression by Northern blot
Total cellular RNA was isolated from HUVECs using TRIzol Reagent (Life Technologies Inc). Northern blot analysis was performed as described. 13 RNA blots were hybridized overnight at 57°C in a hybridization oven with 10 6 cpm/ml of the [α-32P]dATP-labeled oligonucleotide probes for BMP-2 or cDNA for β-actin. Blots were then washed, air dried and exposed to Hyperfilm X-ray films (Amersham) at -80°C.
BMP-2 protein expression by Western blot
The cells in dishes were washed three times in phosphate-buffered saline (PBS), lysed in 250 μl lysis buffer (50 mmol/l Tris-HCl, pH 8.0, 150 mmol/l NaCl, 0.02% sodium vandate, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholic acid, 100 μg/ml PMSF (phenylmethyl sulfonylfluoride), 0.2 μg/ml leupeptin, 1% NP-40). Samples were separated on 12% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electropheresis) gel, and transferred onto PVDF (polyvinylidene difluoride) filters by a wet transferring system. The membrane was blocked with Blotto-Tween (5% non-fat milk and 0.05% Tween 20 in PBS) and incubated with the primary antibodies against BMP-2, CuZnSOD and βactin for 2 h at room temperature. After that, horseradish peroxidase-conjugated secondary IgG was added for 1 h at room temperature. The blots were developed according to the enhanced chemiluminescence protocol (Zhongshan Biotechnology, Beijing).
Measurement of MDA and BMP-2, and activities of total SOD of cell culture MDA levels in conditioned media were measured as thiobarbituric acid-reactive substances as previously described. 14, 15 Thiobarbituric acid-reactive substances were extracted in a mixture of butanol and pyridine, which were separated by centrifugation. Activities of total SOD in cell lysat were measured photometrically according to standard protocols and expressed as units per milligram protein. 16, 17 We developed a sandwich ELISA method to measure BMP-2 levels. BMP-2 levels in culture media were quantified using an enzyme-linked immunosorbent assay (ELISA) from R&D Systems (Minneapolis, MN, USA). According to the manufacturer, there is no known cross-reactivity with other known cytokines in this assay. The sensitivity for BMP-2 was 29 pg/ml in media. Each experiment was done using three replicate wells for each condition, and supernatants from each well were tested in a single ELISA. The intra-assay and interassay coefficients of variation were 4.9% and 6.9%, respectively.
Immunohistochemistry
HUVECs treated by medicine were grown on sixwell glass slides separately and fixed in acetone. After washing in PBS, cells were incubated in a 1% H 2 O 2 solution at room temperature for 10 min to quench endogenous peroxidases. Non-specific binding was blocked with 5% normal horse serum at room temperature for 5 min. The cells were then incubated with anti-NF-κB65 monoantibody (Zhong Shan Biotechnology Co, China) at a NF-κB65 1/200 dilution at 4°C overnight. Following washing in PBS, the secondary antibody, biotinylated antirat, was added and the cells were incubated at room temperature for 1 h. After washing in PBS, vectastain reagent was added and then incubated at room temperature for 10 min. 3,3-Diaminobenzidine was used as the chromagen. After 10 min, the brown color signifying the presence of antigen bound to antibodies was detected by light microscopy and photographed at ×400. Samples from each group were graded for histopathological changes and immunohistochemistry staining. Quantification of perinuclear staining was accomplished by image processing software (MPIAS-500).
Effect of administration of agents on cytoplasmic and nuclear levels of NF-κB p65
The effect of agents on activation of NF-κB in HUVECs was determined using an assay kit from Active Motif (Carlsbad, CA, USA). This kit measures free p65, which is generated when NF-κB is activated. To obtain assay material, the cells were seeded at 1.0 × 10 6 cells/25 cm 2 flask. The cells were harvested at 12 h after addition of these medicines. Cytoplasmic and nuclear cell fractions were collected using the reagents supplied in the Nuclear Extract Kit (Active Motif). The cells were harvested by scraping and were pelleted by centrifugation at 2000 × g at 4°C for 75 s. The pelleted cells were resuspended in 200 μl of hypotonic buffer and incubated on ice for 15 min. Nonidet P-40 (Sigma), a solubilizing agent, was added and the cells were vortexed for 10 s. The material was centrifuged for 45 s at 14,000 × g at 4°C. The supernatant fluids (cytoplasmic fractions) were transferred to pre-chilled microcentrifuge tubes and stored at -80°C. The nuclear pellets obtained above were resuspended in a lysis buffer supplied in the kit, and then vortexed for 10 s. This suspension was incubated for 30 min on ice on a rocking platform, vortexed for 30 s, and then centrifuged for 10 min at 14,000 × g at 4°C.
The supernatant fluids (nuclear fractions) were transferred to pre-chilled microcentrifuge tubes and stored at -80°C. To assay the nuclear and cytoplasmic samples for amounts of p65, 20 μl samples were added to wells of a 96-well plate, coated with an oligonucleotide containing an NF-κB consensus binding site. The p65 subunit of the activated NF-κB contained in cell extracts specifically binds to this oligonucleotide. The plate was incubated for 1 h at room temperature on a rocking platform. After washing, an antibody to p65 was added and incubated for 1 h at room temperature. The wells were then washed, and an HRP-conjugated antibody was added and incubated for 1 h at room temperature. After washing, a substrate solution was added to the wells and incubated at room temperature for 10 min, protected from light. Stop solution (2N H 2 SO 4 ) was added and the absorbance was read at 450 nm. Amounts of protein in the fractions were determined by a modification of the method of Lowry. 18, 19 Results were expressed as Abs. 450 nm/mg protein, and expressed as % control (amount made by cells exposed to control medium, set at 100%).
Statistical analysis
Data are expressed as mean ± SD, and means were compared by one-way ANOVA. The Tukey-Fisher least significant difference (LSD) criterion was used to judge statistical significance. Statistical differences were considered significant at a value of p < 0.05 for all tests.
Results
Induction of BMP-2 and CuZnSOD expression in HUVECs
The mRNA levels in HUVECs are shown in Figure 1 . Under control conditions, very low BMP-2 mRNA levels were found, but incubation of HUVECs with Ang II alone led to a significant increase; however, Ang II-induced BMP-2 mRNA expressions were suppressed by irbesartan or PDTC treatment. BMP-2 and CuZnSOD protein expressions were detected by Western blot (Figure 2 ). We demonstrated that Ang II significantly increased the protein amount of BMP-2, which was inhibited by treatment with irbesartan or PDTC. Our study has also shown that protein expressions of CuZnSOD were down-regulated by Ang II treatment, but were upregulated by irbesartan or PDTC treatment.
Effect of agents on NF-κB p65 levels in HUVECs
NF-κB p65 activation was detected using immunohistochemistry. In the general condition, NF-κB65 protein can only be seen in the endochylema. Our results demonstrate a significantly higher staining of NF-κB65 protein expression in the nucleus of Ang IItreated cells, which was blocked by treatment with irbesartan or PDTC (Table 1 and Figure 3 ). The effects of agents on activation of NF-κB in HUVECs were also determined by an assay kit from Active Motif. Compared with the control group, Ang II caused a significant increase in nuclear p65 levels, reaching a maximum of approximately 10-fold after Ang II treatment, but which were decreased by administration of PDTC or irbesartan. In the cytoplasm of these cells, we also saw an increase in p65 by treatment with Ang II, which was also inhibited by PDTC or irbesartan treatment ( Table 2) .
Measurement of MDA and BMP-2 in culture media and activities of total SOD in cell lysat
To confirm the results of BMP-2 protein production in HUVECs, we also assayed the BMP-2 protein levels by ELISA. Figure 4A shows the increase of BMP-2 levels caused by Ang II; however, Ang II combined with irbesartan or PDTC caused a 
Discussion
BMP-2 plays an important role both in vascular development and in pathophysiological processes.
Mice genetically engineered to be deficient in BMP-2 die between days 7 and 10 of gestation of cardiac defects before bone formation, which suggest the significant importance of BMP-2 in cardiovascular development. 20 Artery wall cells grown in culture were induced to become osteogenic by inflammatory and atherogenic stimuli. 4 BMP-2 and BMP-4 have been most frequently associated with calcific arteriopathy. 2 This evidence showed that BMP-2 plays significantly important roles in bone development and the development of a wide array of tissues outside of bone. 2, 3 Ang II stimulates atherosclerosis through various processes such as endothelial dysfunction, cellular proliferation and inflammation. 21 Ang II elicits the production of superoxide anion, a reactive oxygen species (ROS), from arterial endothelial cells and smooth muscle cells (SMCs). 22 Neutralization of the actions of Ang II by irbesartan exerts antihypertensive and anti-inflammatory effects. 23, 24 Importantly, some evidence has shown that Ang II can elicit significant increases in vascular H 2 O 2 generation, which is an important mediator of NF-κB activation in endothelial cells. 25, 26 Vascular BMP-2 expression can be regulated by H 2 O 2mediated activation of NF-κB both by inflammatory stimuli and high intravascular pressure, so we could hypothesize that Ang II activates BMP-2 expression via NF-κB activation. In our study, we demonstrated that Ang II significantly increased BMP-2 expression associated with NF-κB activation. However, PDTC or irbesartan treatment not only inhibited Ang II-induced BMP-2 expression but also significantly reduced expression of NF-κB 65 protein levels in the nucleus of Ang II-treated cells. Much evidence has shown that NF-κB, as an kind of oncogenic protein, can regulate transcription of a variety of cellular genes, including immune and inflammatory response and growth control. 27, 28 Our findings suggest the activa-tion of NF-κB may be an important signal transduction pathway in the effects of Ang II uptake BMP-2 expression.
The interesting findings by Csiszar was that high pressure is sufficient to induce BMP-2 expression in vitro and exhibit an increased ROS production, and this study also indicated that H 2 O 2 production is an important mediator of NF-κB activation in endothelial cells; 2 however, this study did not verify whether Ang II induces BMP-2 expression in HUVECs. They used Ang II only to build up the animal model of hypertension. Importantly, some evidence has shown that Ang II can elicit significant increases in vascular H 2 O 2 generation, 25,26 so we could assume that Ang II might activate BMP-2 expression via NF-κB activation. Indeed, our study demonstrated that administration of Ang II was associated with nuclear translocation of NF-κB. The view was further supported by our findings that Ang II-induced activation of NF-κB was significantly decreased by PDTC treatment. Immunohistochemistry confirmed that Ang II-induced nuclear accumulation of activated NF-κB was particularly prevalent in the nuclei of endothelial cells. Our study showed that Ang II elicited NF-κB activation, which is likely responsible for Ang II-induced BMP-2 expression.
The present study was also to evaluate the oxidative status by detecting the activity of SOD together with the level of MDA, a well-known marker of oxidative stress. Our study showed that the increasing MDA levels and decreasing activities of total SOD levels caused by Ang II were reversed by irbesartan or PDTC treatment. These findings suggest that the excessive oxidative stress occurred during Ang II status. However, PDTC or irbesartan treatment significantly reduced MDA concentration, suggesting that irbesartan had a strong antioxidative property, which was supported by the previous study. 29 In conclusion, Ang II-induced BMP-2 expression was suppressed by PDTC or irbesartan treatment. Ang II-induced BMP-2 expression might involve excessive oxidative stress.
